ArticleRespiratory research2026
Recombinant SARS-Cov-2 spike protein S1 subunit upregulates P2 × 7-NLRP3 leading to macrophage pyroptosis promoting acute lung injury.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Let-7a-5p/SHIP-1 Axis Drives SARS-CoV-2 Spike-1-Induced Microglial Pyroptosis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOur previous study confirmed recombinant SARS-CoV-2 spike protein subunit S1 (S1SP) independently induces acute lung injury (ALI), but its mechanism remains unclear. This study thoroughly investigates the role of the purinergic receptor P2 × 7 and its downstream NLRP3 inflammasome in S1SP-induced lung injury.
methodsS1SP was used to intervene in humanized K18-hACE2 mice and THP-1 cells. In vivo, mice were divided into Control, S1SP, S1SP + MCC950 (NLRP3 inhibitor), S1SP + A438079 (P2 × 7 antagonist) and their respective control groups to study the effect of S1SP on NLRP3 inflammasome in mouse lung tissues. In vitro, THP-1-derived macrophages were grouped as Control, S1SP + ATP, S1SP + ATP A438079 and A438079 control groups. qRT-PCR was used to measure NLRP3, Caspase-1 and P2 × 7 mRNA levels. Immunofluorescence and western blot detected related proteins, and ELISA measured IL-1β and IL-18 levels in bronchoalveolar lavage fluid (BALF).
resultsS1SP caused severe lung injury, edema, and elevated ATP in BALF. NF-κB and NLRP3 inflammasome activation led to increased TNF-α, IL-6, and Gasdermin D N-terminal fragment (GSDMD-NT) (p < 0.05). NLRP3 and P2 × 7 co-localized with macrophages, indicating their central role. MCC950 or A438079 reduced tissue damage, restored tight junction integrity, and suppressed IL-1β/IL-18 release. In vitro, S1SP + ATP co-stimulation upregulated P2 × 7 and NLRP3 activity in macrophages, exacerbating pyroptosis and cytokine release.
conclusionP2 × 7 receptor mediates the occurrence of cellular pyroptosis in macrophages through the upregulation of its downstream NLRP3 inflammasome activity, contributing to the expression and release of inflammatory factors, which in turn promotes the onset and progression of S1SP-induced ALI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.